Eli Lilly at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Eli Lilly brings 2 presentations to ENA 2026 in Barcelona. Its posters cover a new antibody-drug conjugate and a combination strategy for targeted therapy. LY4402289 targets DLL3 and carries a NAMPT inhibitor payload, while vepugratinib is shown to make FGFR3-altered urothelial cancer cells sensitive to HER2-targeted therapies.
| Organization | ENA 2026 Attendance |
|---|---|
Eli Lilly Indianapolis, Indiana | |
Global pharmaceutical company; its oncology portfolio includes kinase inhibitors and antibody-drug conjugates in development. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from Eli Lilly
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction